heat biologics is a clinical-stage company focused on developing its proprietary impact™ (immune pan-antigen cytotoxic therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. heat's impact therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. impact effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. impact therapy is applicable to a wide range of cancers. heat is currently conducting two phase 2 clinical trials with its hs-110 to treat non-small cell lung cancer (nsclc) and its hs-410 to treat bladder cancer.
![Scorpius logo](/files/LOGO/1476963-placeholder.png)
Company profile
Ticker
SCPXD
Exchange
Website
CEO
Jeffrey Wolf
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
HEAT BIOLOGICS, INC., NightHawk Biosciences, Inc.
SEC CIK
Corporate docs
Subsidiaries
Heat Biologics I, Inc • Heat Biologics III, Inc. • Heat Biologics IV, Inc. • Heat Biologics GmbH • Heat Biologics Australia Pty LTD • Zolovax, Inc. • Scorpius Biomanufacturing, Inc. • 1Formerly Heat Biologics II, Inc. ...
IRS number
262844103
SCPXD stock data
Latest filings (excl ownership)
S-1
IPO registration
18 Jul 24
8-K
Scorpius Holdings Announces Reverse Stock Split
18 Jul 24
ARS
2023 FY
Annual report to shareholders
17 Jun 24
DEF 14A
Definitive proxy
17 Jun 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Jun 24
PRE 14A
Preliminary proxy
5 Jun 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 May 24
8-K
Scorpius Holdings Achieves 359% Year-Over-Year Increase in Revenue for the First Quarter of 2024
29 May 24
10-Q
2024 Q1
Quarterly report
28 May 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 May 24
Latest ownership filings
SC 13D/A
Wolf Jeffrey Alan
21 May 24
4
Jeffrey Alan Wolf
17 May 24
SC 13D/A
Wolf Jeffrey Alan
14 May 24
SC 13D/A
Wolf Jeffrey Alan
12 Dec 23
SC 13D/A
Wolf Jeffrey Alan
21 Aug 23
SC 13D/A
Wolf Jeffrey Alan
30 Dec 22
4
Jeffrey Alan Wolf
9 Dec 22
4
Edward B Smith III
9 Dec 22
4
JOHN K A PRENDERGAST
9 Dec 22
4
William L. Ostrander
9 Dec 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.55 mm | 1.55 mm | 1.55 mm | 1.55 mm | 1.55 mm | 1.55 mm |
Cash burn (monthly) | (no burn) | 522.66 k | 1.77 mm | 3.13 mm | 1.56 mm | 1.87 mm |
Cash used (since last report) | n/a | 2.03 mm | 6.89 mm | 12.16 mm | 6.06 mm | 7.26 mm |
Cash remaining | n/a | -474.68 k | -5.33 mm | -10.60 mm | -4.51 mm | -5.70 mm |
Runway (months of cash) | n/a | -0.9 | -3.0 | -3.4 | -2.9 | -3.1 |
Institutional ownership, Q1 2024
2.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 8 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 61.76 mm |
Total shares | 1.97 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 1.62 mm | $11.13 mm |
Warberg Asset Management | 283.04 k | $45.85 mm |
BK Bank Of New York Mellon | 14.60 k | $2.37 mm |
Edmond De Rothschild Holding | 14.29 k | $2.31 mm |
Wolf Jeffrey Alan | 11.03 k | $4.00 k |
FNY Investment Advisers | 10.00 k | $1.00 k |
Asset Dedication | 6.50 k | $1.00 k |
Cutler | 5.00 k | $0.00 |
Mendota Financial | 285.00 | $47.00 k |
Huntington National Bank | 220.00 | $36.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 May 24 | Wolf Jeffrey Alan | Common Stock | Grant | Acquire A | No | No | 0 | 2,500,000 | 0.00 | 3,572,789 |
16 May 24 | Wolf Jeffrey Alan | Warrant Common Stock | Grant | Acquire A | No | No | 0.12 | 2,500,000 | 300.00 k | 2,500,000 |
News
Scorpius Holdings Board Approves 1-For-200 Reverse Stock Split Of Common Stock
17 Jul 24
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
17 Jun 24
US Stocks Mixed; Dow Tumbles Over 100 Points
17 Jun 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
4 Jun 24
Scorpius And Beyond Imagination Announce Partnership To Utilize Autonomous AI-Powered Humanoid Robots For American Biomanufacturing
3 Jun 24
Press releases
Scorpius Holdings Announces Reverse Stock Split
17 Jul 24
Scorpius Holdings Achieves 359% Year-Over-Year Increase in Revenue for the First Quarter of 2024
29 May 24
Scorpius Holdings, Inc. Announces Closing of Public Offering
16 May 24
Scorpius Holdings Commends Congress on Bipartisan Legislative Action Aimed at Bolstering U.S. Biomanufacturing
16 May 24
Scorpius Holdings, Inc. Announces Pricing of Public Offering
14 May 24